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Review

Capturing functional epigenomes for insight into
metabolic diseases
Fiona Allum 1, 2, Elin Grundberg 3, *
ABSTRACT
Background: Metabolic diseases such as obesity are known to be driven by both environmental and genetic factors. Although genome-wide
association studies of common variants and their impact on complex traits have provided some biological insight into disease etiology, identiﬁed genetic variants have been found to contribute only a small proportion to disease heritability, and to map mainly to non-coding regions of the
genome. To link variants to function, association studies of cellular traits, such as epigenetic marks, in disease-relevant tissues are commonly
applied.
Scope of the review: We review large-scale efforts to generate genome-wide maps of coordinated epigenetic marks and their utility in complex
disease dissection with a focus on DNA methylation. We contrast DNA methylation proﬁling methods and discuss the advantages of using targeted
methods for single-base resolution assessments of methylation levels across tissue-speciﬁc regulatory regions to deepen our understanding of
contributing factors leading to complex diseases.
Major conclusions: Large-scale assessments of DNA methylation patterns in metabolic disease-linked study cohorts have provided insight into
the impact of variable epigenetic variants in disease etiology. In-depth proﬁling of epigenetic marks at regulatory regions, particularly at tissuespeciﬁc elements, will be key to dissect the genetic and environmental components contributing to metabolic disease onset and progression.
Ó 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Metabolic diseases such as obesity are known to be multifactorial in
nature, with genetic and environmental factors underlying disease
onset (Figure 1) [1e4]. Case-control-based genetic studies of clinically
ascertained obesity status have returned few cohesive results [5], most
likely due to the heterogeneity of this condition. Conversely, quantitative genetic studies of complex traits related to metabolic diseases
have successfully hinted at essential biological pathways involved in
trait etiology; for instance, the central nervous system in genome-wide
association studies (GWAS) of body mass index (BMI) [5e8] and
adipogenesis in GWAS of waist-to-hip ratio [5,9]da measure of
abdominal adiposity. However, disease and trait-linked common genetic variants (i.e., single nucleotide polymorphisms; SNPs), per se,
have been assessed to contribute only a limited proportion to the
overall trait variance. Tabulations of total contributions vary from study
to study and continue to improve with cohort sizes and the advent of
statistical methods. For instance, the predicted genetic contribution to
the obesity-related trait of BMI was initially assessed from twin studies
to be between 40 and 70% [10e12], but alternative statistical
methods have suggested that these numbers may be overestimated,
and rather range from 30% to 40% [13]. Nevertheless, most reports
have estimated that identiﬁed GWAS SNPs cumulatively account for
less than 5e15% of observed variance, with geneegene and genee

environment effects and lack of coverage of rare variants suggested to
contribute to the underestimation of identiﬁed trait-linked loci [14].
In addition, the majority of disease and trait-linked SNPs have been
shown to locate to the non-coding portion of the genome and, more
speciﬁcally, to the active chromatin in cells linked to the disease under
study [15e19]ewhere the target gene affected is usually unknown. As
such, ﬁndings from GWAS alone have not been easily translated into
new biological mechanisms. Integrational approaches that layer additional association studies of cellular traits are required to functionally
annotate these trait-linked SNPs. For this purpose, genome-wide gene
expression assessments in genotyped tissue or cell samples from
populations remain a common approach for functional analysis of disease SNPs and are referred to as expression quantitative trait loci (eQTL)
analysis. Large-scale efforts to generate eQTL maps across multiple
tissues e such as those by the Genotype-Tissue Expression (GTEx)
consortium -have showed that SNP-expression associations have a
strong tissue- and cell-speciﬁc component. As such, the results from
these studies have pointed toward the need for careful consideration in
tissue selection for the integrational functional analysis of disease SNPs
to gain additional insight into disease etiology [20e25].
Annotation efforts have more recently been extended to expressionmodulating epigenetic traits such as DNA methylation (50 methylcytosine) levels (methylation QTL; metQTL) or chromatin mark peaks
(histone QTL; hQTL) with the same purpose as eQTL studies, which is

1

Department of Human Genetics, McGill University, Montréal, Québec, H3A 0C7, Canada 2McGill University and Genome Quebec Innovation Centre, Montréal, Québec, H3A
0G1, Canada 3Children’s Mercy Kansas City, Kansas City, MO, 64108, United States
*Corresponding author. E-mail: egrundberg@cmh.edu (E. Grundberg).
Received September 27, 2019



Revision received December 23, 2019



Accepted December 30, 2019



Available online 14 February 2020

https://doi.org/10.1016/j.molmet.2019.12.016

MOLECULAR METABOLISM 38 (2020) 100936 Ó 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

1

Review

Figure 1: Summary of complex diseases and trait drivers. Graphical representation of contributing factors underlying complex disease risk including the interplay between
environmental and genetic factors (black arrows) that impact epigenetics traits and provide insight into molecular mechanisms underlying disease etiology (gray arrows). This
potential “causal pathway” (solid arrows) involving epigenetic changes impacting phenotype and disease is distinguished from a “reactive pathway”, in which the phenotype or
disease state causes an epigenetic change (dotted arrow). Epigenetic traits are referred to here by CpG (DNA) methylation and histone modiﬁcations. Methylated CpGs are shown in
orange and unmethylated CpGs are depicted in purple. Similarly, histone tails enriched in modiﬁcations correlating to inactive chromatin are shown in yellow (i.e., H3K9me2/3 and
H3K27me3) and those enriched at active regulatory elements are presented in pink (i.e., H3K4me1, H3K4me3, and H3K27ac). Figure was created with Biorender.com.

to inform about functional consequences of disease SNPs. Epigenetic
traits are not only known to have similarly cell-speciﬁc signatures, but
are also associated with stable long-term alterations caused by both
genetic and environmental factors (Figure 1). In this way, genomewide assessment of epigenetic traits, often referred to as epigenome
mapping, can be used to gain biological insight into the disease model
by enabling us to correlate genetics and environment to disease-linked
phenotypes. With the tight link between epigenetic marks and gene
activity regulation, epigenome mapping focuses on regulatory element
proﬁling. Here, the proximal promoter regions can be more easily
annotated as they usually contain the transcription start site (TSS) of
genes. On the other hand, distal regulatory regions (i.e., enhancers) are
more difﬁcult to identify. These elements serve to modify the transcription rate of genes (proximal and/or non-proximal), which they
physically contact through chromatin looping secured by protein interactions. Genome-wide identiﬁcation of these regions poses
challenges in the ﬁeld, as gene expression is dependent on the
differentiated nature of cells and is spatially and temporally modulated.
Here, we aim to provide a review of the current literature on accessing
and assessing high-resolution epigenetic signatures, mainly DNA
methylation, with a speciﬁc focus on metabolic disease studies. We
emphasize the beneﬁt of using integrational studies by layering
available epigenomic maps from large-scale consortium efforts, as
well as recent efforts investigating regulatory regions in tissues and
cells linked to the disease model for increased discovery power of
novel disease genetic and epigenetic variants.
2. CONSORTIA EFFORTS TO DEFINE EPIGENOME MAPS
The Human Genome Project (HGP) was a ground-breaking collaborative
effort that paved the way for subsequent large-scale projects [26,27] by
providing the scientiﬁc community with the ﬁrst map of the human
genome. With the realization that the human genome was composed to
a large extent of non-coding DNA for which functional interpretation was
lacking, functional genomics studies gained attention to assign genomic
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roles and identify regulatory elements [26]. To this end, the National
Human Genome Research Institute (NHGRI) launched The Encyclopedia
of DNA Elements (ENCODE) project in 2003, with the purpose of
providing detailed maps of regulatory elements across the human
genome [28,29]. With the ENCODE project focusing on cultured cell lines
for genome characterization, the subsequent National Institutes of
Health (NIH) Roadmap Consortium shifted toward providing reference
epigenome mapping in ex-vivo tissues and primary cells [30]. In 2015,
these efforts culminated in the public release and integrative analysis of
over 100 reference human epigenomes [16]. These reference epigenome efforts were uniﬁed with similar consortia from North America,
Europe, Australia, and Asia to form The International Human Epigenome
Consortium (IHEC), with the goal of providing access to over 1000
complete human epigenome proﬁles [31]. One focus area of the consortium is the analysis of cells connected to metabolic diseases, such as
obesity and steatosis. As of the latest IHEC portal (http://epigenomes.ca/
ihec) release (2018-10; hg19 reference), there are 824 metabolic
disease-relevant epigenomes derived from various adipose depots,
liver, muscle, gastrointestinal, and brain tissues, generated from six
consortia efforts (Figure 2). Other more-targeted studies have also
contributed valuable reference and population epigenome maps,
including DNA methylation proﬁles of adipocytes [32], subcutaneous
and visceral adipose tissues [33e35], open chromatin maps of adipocytes [34], and transcriptome proﬁles of adipocytes [32,34], subcutaneous adipose tissues [21], and liver tissues [36]. Together, these
efforts provide a rich resource of epigenomes to the scientiﬁc community to help decipher the genetic and environmental basis of disease
and regulation of gene expression, as well as advance technological and
statistical methods to discover and interpret epigenomic marks.
3. EPIGENOME ASSAYS IN POPULATION- AND DISEASEBASED STUDIES
Assessing genome-wide epigenetic patterns generated by the consortia has provided us with a wealth of information concerning the
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Figure 2: Metabolic disease-linked tissue epigenome maps from the International Human Epigenome Consortium (IHEC). Publicly accessible epigenome proﬁles from the
IHEC portal (http://epigenomes.ca/ihec;2018-10; hg19 reference). The 824 available datasets are summarized (A) in table format, (B) per consortium, (C) per tissue type, and (D)
per epigenetic mark category. Figure panels were adapted from the IHEC portal graphical content.

relationship between epigenome traits, especially at regulatory elements [16,18]. Active promoter and enhancer elements are characterized by an open chromatin proﬁle, allowing transcription factors to
access the genome and regulate transcription. By mapping open
chromatin across human tissues and cells, we have been able to gain
crucial insight into gene regulation as well as characterize regulatory
elements in greater detail. These open chromatin regions are sensitive
to cleavage by the enzyme DNase I and, consequently, marked by
DNase I hypersensitivity sites (DHS) [37]. Genome-wide mapping of
DHSs is performed by DNaseI-Seq and has provided the ﬁeld of
functional genomics with a reproducible tool to detect these
nucleosome-free (i.e., open and active) DNA regions [38]. The application of DNaseI-Seq in over 125 types of human samples was a
landmark study by ENCODE that showed enhancers displaying celltype-speciﬁc patterns in contrast to promoter elements, which
appeared to be largely shared across cell types and states [39].
Combining these proﬁles with those generated by the NIH Roadmap
showed that GWAS SNPs are speciﬁcally enriched in DHS mined from
human cell types linked to the disease model [17], indicating the
importance of comprehensively capturing regulatory DNA in common
human disease studies. More recently, the Tn5 transposase was
shown to have similar abilities as DNase I in tagging and mapping open
chromatin in an efﬁcient manner, which resulted in the development of

the assay for transposase-accessible chromatin using sequencing
(ATAC-Seq). Since then, ATAC-Seq has enabled investigators to assess
reproducible chromatin proﬁles in previously unexplored cell types
from lower yield samples [40]. Due to its sensitivity and ease of use
over DNaseI-Seq, ATAC-Seq is now commonly applied in large-scale
population-based studies. For instance, a recent study proﬁling
chromatin accessibility in lymphoblastoid cell lines from 100 individuals provided insight into establishing correlation maps between
open (i.e., active) chromatin regions, which may reﬂect threedimensional (3D) chromatin organization in cells [41].
Post-translational modiﬁcations of histones (i.e., histone marks)
represent another type of epigenetic trait studied to assign function
genome-wide. Reports have shown that histone marks are deposited
in a coordinated fashion (i.e., histone code) that correlates to chromatin
states [42]. For instance, mono-methylation at the 4th lysine
(H3K4me1) and acetylation at the 27th lysine residue of the histone H3
protein (H3K27ac) are often associated with active enhancers [43],
whereas tri-methylation at the 4th lysine of the histone H3 protein
(H3K4me3) correlates with active promoter regions [44]. In contrast,
inactive chromatin has been noted to be depleted of these marks and,
instead, demarcated by other histone modiﬁcations such as trimethylation of H3K27 (H3K27me3). In addition, silent genes have
been associated with di- and trimethylation of H3K9 (i.e., H3K9me2/3)

MOLECULAR METABOLISM 38 (2020) 100936 Ó 2020 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com

3

Review
[45e48]. Using an unsupervised statistical model [15] to predict
chromatin states based on these histone marks, Ernst et al. were able
to show that GWAS SNPs are enriched in enhancer regions of cell types
speciﬁcally linked to the associated disease or trait [49]. Focusing on
the metabolic disease aspect, SNPs correlated to blood lipids and
triglycerides were shown to map preferentially to distal regulatory
regions deﬁned for hepatocellular carcinoma (HepG2) cells [49]. More
recently, similar integrational approaches have been applied
combining both open chromatin and histone mark signatures in large
meta-analyses of metabolic disease GWAS. For instance, Mahajan
et al. ﬁne-mapped type 2 diabetes loci at single-variant resolution [50]
using pancreatic islet-speciﬁc chromatin proﬁles generated through
ATAC-seq and chromatin states inferred from combinations of histone
marks [51e53]. Similarly, Inoue et al. used ATAC-seq and H3K27ac
ChIP-seq-derived epigenomic maps generated in leptin-responsive
neurons to ﬁne-map obesity-related GWAS SNPs [54].
Whereas these previously discussed epigenetic traits and related assays represent qualitative measures of genome function, DNA (CpG)
methylation offers a quantitative measure (between 0 and 100%) at
almost 30 million sites genome-wide. This feature accounts in part for
the popularity of DNA methylation in epigenome-wide studies of
complex traits. As such, we focus the remainder of this review on DNA
methylation and complex disease studies.
4. COORDINATED PATTERNS OF METHYLOMES DEFINE
REGULATORY REGIONS
As previously discussed, genome function, with its regulatory regions,
can be deﬁned by chromatin activity and histone modiﬁcations, but can
also be inferred from DNA methylation patterns by taking methylation
level and CpG density into account [18,39]. Regions of low to unmethylated CpGsdso-called hypomethylated footprintsdare known to
correspond with transcription factor occupancy and active chromatin
states [55,56]. Speciﬁcally, dense regions of CpGs together with very
low CpG methylation state often occur close to transcription start sites
and, thus, reﬂect promoter regions. In contrast, regions of low CpG
density together with intermediate CpG methylation overlap H3K27ac
marks, linking them to enhancer regions. These enhancer-like hypomethylated footprints have further been found to show high overlaps
with cell-type-speciﬁc DHS and transcription factor binding motifs [56],
supporting their validity. Mechanistically, Yin et al. have recently shown
that the hydrophobic nature of the methyl group at methylated CpGs is
an important contributing selection factor in promoting or deterring
transcription factor binding afﬁnity [57]. To assign CpG methylation
signatures to regulatory elements genome-wide, statistical models
have been developed for use on next-generation single-base resolution
methylation proﬁles. For instance, MethylSeekR uses a Hidden Markov
Model to identify unmethylated (UMR) and low-methylated regions
(LMR) based on average methylation status and total CpG density [56].
Studies have shown that UMRs are more likely to be shared across cell
types or tissues, whereas LMRs are more prone to be tissue-speciﬁc
[56,58]dreﬂecting the expected behaviors of promoters and enhancers, respectively. Speciﬁcally, Busche et al. investigated hypomethylated footprints within methylomes of w30 matched
subcutaneous adipose and whole-blood tissues, identifying w60,000
regulatory regions per tissue with 30% being UMRs and the remainder
LMRs [58]. UMRs were found to exhibit longer fragment lengths
(w2400 bp) and 90% shared identity across tissues, whereas LMRs
were found to be shorter (w750 bp) and more tissue-speciﬁc (45%
shared) [58]. Importantly, identiﬁed adipose hypomethylated footprints
depicted distinguishing enrichments for histone marks derived from
4

human adipocytes (NIH Roadmap); UMRs were enriched for H3K4me3
marks, whereas LMRs were more likely to overlap H3K4me1 marks
[58]. These reported coordinated patterns of epigenetic marks indicate
that inferring regulatory elements from methylation proﬁles alone (i.e.,
without the need for parallel assessments of histone modiﬁcations) is a
valid strategy in the analysis of the functional epigenome in disease
studies.
5. ASSESSING VARIATION OF METHYLOMES IN METABOLIC
DISEASE STUDIES
Surveys of genome-wide methylome signatures proﬁled across various
human tissues and cell types as well as in populations have demonstrated that a large fraction of the methylation landscape (up to 80%) is
hypermethylated [59] and displays a relatively static pattern [59,60].
These invariable CpGs were also shown to co-localize outside of
regulatory regions, further distinguishing them from the subset
(w15e20%) of CpGs with dynamic regulation, which are hypomethylated, map mainly to distal regulatory elements (i.e. enhancers)
and transcription factor binding sites, as well as associate with tissuespeciﬁc functions [55,59]. Schultz et al. provided further evidence of
this in their genome-wide methylome survey of 18 different human
tissues across four individuals, showing, for example, that hypomethylated regions of dynamic CpGs in the aorta overlap aorta-speciﬁc
enhancers [60]. Similarly, a large-scale investigation of adipose
methylation proﬁles from w600 twins of the Multiple Tissue Human
Expression Resource (MuTHER) conﬁrmed this CpG variability pattern,
with dynamic CpGs observed to be enriched within intergenic regions
including those marked by H3K4me1 in human adipocytes [33]. The
study also presented evidence that variable CpGs in adipose tissue are
more likely to be under genetic regulation, with a subset of
methylation-linked SNPs overlapping GWAS SNPs of metabolic phenotypes [33]. A similar enrichment of genetic regulation at populationvariable CpGs was reported by Schultz et al., showing a w1.6-fold
enrichment of SNPs associating with dynamic regions of CpG
methylation. Complementary to this, a more recent investigation of
hypomethylated footprints in w200 human visceral adipose tissue
samples found that metabolic trait-linked CpGs not only map preferentially to enhancer regions, but are under strong genetic effects, with
this genetic regulation being distinctively augmented at signals shared
across tissue types to whole blood [35]. The aforementioned efforts
strongly point to the importance of considering genomic background
for functional interpretation of CpG methylation in relation to disease
[61]. Speciﬁcally, full investigation of regulatory elements in diseaselinked tissues will provide additional insight into complex disease
etiology, prompting the implementation of targeted approaches for the
assessment of methylome variation in disease association studies as
discussed in the following section.
6. METHODS TO ASSESS GENOME-WIDE METHYLOME
PROFILES
With the increased interest in linking epigenome proﬁles to disease
status or trait variation in populations, various approaches suitable for
large-scale assessments have been presented. Current methods for
genome-wide assessment of individual CpG methylation status can be
distinguished by their proﬁling methodology (i.e., microarray or nextgeneration sequencing (NGS)-based) and their genome coverage capacity (i.e., targeted vs. genome-wide). Whole-genome bisulﬁte
sequencing (WGBS) is an NGS method that represents the gold standard in methylation assessment, wherein all CpGs (w30M CpGs in the
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human genome) may be captured at single-base resolution, depending
on the sequencing depth. Although the application of this method
represents an advantageous and unbiased solution, the high cost of
proﬁling the entire methylome currently limits the use of WGBS in large
epigenome-wide association studies (EWAS). As stated previously,
WGBS across human tissues and in populations has demonstrated that
only a fraction of the methylation landscape (w20%) is variable [59],
supporting a more practical solution for the assessment of the informative fraction of the methylome. In response to the high costs of
WGBS, reduced representation bisulﬁte sequencing (RRBS) was presented as an alternative sequence-based method for methylation
proﬁling. This enrichment-based methodology enables researchers to
capture fragments from WGBS libraries that show afﬁnity to the MspI
restriction enzyme. Due to the binding motif of this enzyme, RRBS
enriches for CpG-dense regions, such as promoters, CpG islands, and
genic regions, at the cost of coverage at distal regulatory regions. A
recent RRBS-based EWAS of 32 metabolic disease-related measurements within the population-based Metabolic Syndrome in Men
(METSIM) Study revealed novel but limited number of disease-linked
epigenetic regions (N ¼ 21) in subcutaneous adipose tissue [62]. In
line with known limitations of RRBS, a higher proportion of regions
were observed to map to intragenic regions over intergenic regions.
Nevertheless, in concordance with current epigenomic trends, a large
fraction of the regions associated with the tested metabolic disease
traits (i.e., 6 of 21) were found to overlap enhancer-like adipocytederived histone marks from the NIH Roadmap (i.e., H3K4me1 and
H3K27ac) [62]dregions that were overall underrepresented in this
study due to the preferential capture of dense CpG regions by RRBS.
A more popular method that has been applied in large-scale methylation proﬁling studies of common disease traits is the microarraybased Inﬁnium Human Methylation450 Beadchip (450K) array [63],
which was recently replaced by the more comprehensive Inﬁnium
MethylationEPIC (EPIC) array [64]. These array methods depend on the
hybridization capability of DNA followed by single-base extension and
assessment at w480,000 and w850,000 CpG sites, respectively.
Although very practical and cost-efﬁcient to implement in the laboratory, the lack of CpG coverage and tissue-speciﬁcity provided by these
“one-size-ﬁts-all” methods can be limiting in disease studies. In fact,
genomic annotation analyses have shown that these technologies are
similar to RRBS, in that they are biased to CpGs located in densely
populated promoter regions, which, as indicated previously, are prone
to have less variable methylation levels. Conversely, distal regulatory
regions containing dynamic CpGs are underrepresented on these arrays, indicating that these technologies do not permit the full
assessment of the disease-linked methylome [33,35,59]. More precisely, the 450K array probes were selected to interrogate primarily
elements of the RefSeq genes including CpG Islands and nearby shores
and shelves, 50 UTR, 30 UTR, as well as gene bodies e together representing w75% of the total panel [33,63]. The EPIC array builds on
the 450K array by retaining w94% of targeted sites from this method
while aiming to proﬁle additional distal regulatory elements deﬁned by
the FANTOM5 and ENCODE [64]. A 2016 report on the EPIC array
method showed that 58% of probes on the chip interrogated CpGs
located to FANTOM5-deﬁned enhancers, but only 7% mapped to
ENCODE distal regulatory regions. Still, these numbers represent an
improvement of coverage at these types of elements over the 450K
array, where only an 18% and 3% overlap were noted, respectively
[64]. Congruently, in their assessments of w300 human skeletal
tissues, Taylor et al. remarked that proﬁling with the EPIC array limits
the capacity to capture tissue-linked CpGs for use in cellular deconvolution analyses [65]. All the more, the majority of EWAS investigating

metabolic traits have relied on these user-friendly array-based technologies. These methods have been applied predominantly to cohorts
of bioavailable tissues (i.e., whole-blood), providing information on a
limited number of trait-linked CpGs. For instance, in their 2014 report,
Dick et al. presented a novel sequential replication scheme (N ¼ 2500)
for an epigenome-wide study of BMI in both bioavailable and diseaselinked proxy tissues (subcutaneous adipose tissues) [66]. Their results
highlighted a single regulatory intronic element mapping to HIF3A as
being linked to the disease model [66]. A larger study released in 2017
by Mendelson et al. (N ¼ 8000 whole-blood samples) was able to mine
a total of 83 BMI-linked CpGs enriched in DHS regions and enhancer
regions marked by H3K4me1, thereby indicating the importance of
proﬁling these regions in disease investigations [67]. These trends
were conﬁrmed by Wahl et al. in their epigenome-wide assessment of
whole-blood methylation and BMI in over 10,000 individuals where,
again, the trait-linked CpGs were found to be enriched in active
chromatin marks [68]. Furthermore, studies focusing on correlating
circulating lipids to methylation status in whole-blood tissues have
demonstrated similar ﬁndings with the largest survey (N ¼ 4500) by
Hedman et al. identifying 33 disease-linked CpGs lacking enrichment
in promoter regions [69].
To resolve some of the technical limitations posed by the aforementioned methylome assessment methods, MethylC-Capture Sequencing
(MCC-Seq) was recently introduced as an equally sensitive but more
economical and tissue-speciﬁc tool [34]. MCC-Seq is a NGS-based
method that allows for enrichment of WGBS libraries over userdeﬁned regions (up to 200 Mb) [34]. In this way, MCC-Seq can be
used to strategically capture variable CpGs mapping to tissue-speciﬁc
regulatory regions, thereby allowing users to proﬁle informative
methylomes for disease investigations while incurring comparable
costs to available array-based techniques [34]. Contrary to other
available capture-based methylome sequencing approaches such as
Agilent SureSelect Human Methyl-Seq, MCC-Seq is able to capture
both strands over selected regions, providing precise genotype calls for
downstream imputation of common genotypes [34]. In this way, MCCSeq can be applied as a dual-purpose method that permits concurrent
proﬁling of methylation and genotypes over target regions in a tissue of
interest. Although MCC-Seq can be customized for any tissue, and has
been successfully applied in sperm [70] and whole-blood tissue [71],
the approach was exempliﬁed speciﬁcally for metabolic disease
studies with a target panel of 4 million CpGs mapping mainly to regulatory elements speciﬁc to adipocytes and/or adipose tissue [34,35],
which is discussed in more detail below.
7. FINE-MAPPING FUNCTIONAL METHYLOMES IN METABOLIC
DISEASE STUDIES
Targeted investigations of the active (i.e., functional) portion of the
methylome in metabolic-disease-linked tissues have provided us with
additional insight into the role of regulatory regions in disease etiology.
An epigenome study of 200 visceral adipose tissue samples derived
from individuals with severe obesity but different degrees of metabolic
complications was recently presented [35]. Here, active regulatory
regions in adipose tissue and related cells were targeted by a custom
panel using MCC-Seq proﬁling over 3 million CpGs for methylation
analysis [34,35]. Intersecting these MCC-Seq-captured regulatory regions with those from available array-based methods (i.e., EPIC and
450K) found that only a small proportion of these sites are covered by
these latter techniques (Figure 3). More precisely, the EPIC array
captures only w20% and w30% of the enhancer- and promotermapping CpGs targeted by this adipose MCC-Seq panel, respectively
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Figure 3: Comparison of DNA methylation proﬁling at adipose regulatory regions by available methods. CpGs captured by the 450K array, EPIC array, and MCC-Seq using
the adipose tissue panel published in [34] are contrasted at different genomic regions. Overlaps with typical proﬁles of WGBS in visceral adipose tissue and adipocyte nuclei histone
marks for H3K4me1 and H3K4me3 (NIH Roadmap; donor 92) are also depicted. (A) Lack of coverage by array-based methods can be noted at multiple adipose enhancer elements
mapping to an intergenic region on chr13. (B) The ﬁne-mapping potential by MCC-Seq at the previously identiﬁed HDL-linked 450K array probe [69] locating to an intragenic region
in the MYO5C locus (highlighted in light gray) is exempliﬁed.

[35]. The beneﬁt of dense CpG methylation proﬁling in regulatory elements was reﬂected in the release of expanded catalogues of adipose
regulatory regions (>500 elements per study) associating to metabolic
disease traits [i.e., triglycerides, high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, and total
cholesterol], representing higher discovery power over published
studies [34,35]. As indicated previously, earlier reports of complextrait-linked EWAS depicted disease-associated CpGs to map to
enhancer-like genomic regions, but methods used to generate these
ﬁndings provided only limited surveys of these types of regulatory
regions (Figure 3). The application of MCC-Seq in adipose tissue
permitted the investigation of the full range of distal regulatory regions
as well as promoter regions mined from bioinformatics tools of wholegenome adipose DNA methylation proﬁles (Figure 3). This type of
detailed assessment solidiﬁed observed preliminary reports, as
metabolic disease trait-linked CpGs were found to be distinctively
enriched not only in enhancer regions, but further in tissue-speciﬁc
regulatory regions mapping to both enhancers and promoters
[34,35], both of which are underrepresented in current available
techniques.
The unprecedented resolution of CpG proﬁling by MCC-Seq also
permitted the generation of distinctive positional patterns of metabolic
disease trait-linked CpGs within different types of regulatory elements.
Speciﬁcally, disease-associated CpGs mapping to enhancers were
enriched at the mid-point of these regulatory regions, whereas those
6

co-localizing to promoters depicted a bimodal distribution, with TSS
being less occupied [35], likely reﬂecting speciﬁc transcription factor
(TF) occupancy at these elements. In fact, Grossman et al. used epigenome maps from 47 cell types deﬁned by the NIH Roadmap and
described similar positional trends within enhancers for different
classes of TFs where those associated with cell-type-speciﬁc
expression indeed mapped to the center of enhancers [72]. In line
with this, Allum et al. showed that metabolic disease-associated
regulatory regions were found to be TF binding motif hotspots for
adiposity-linked STAT family proteins and NFIB. These groups of TFs
were also found to depict an adipose-speciﬁc expression pattern [35].
Allum et al. further highlighted the beneﬁt of CpG methylation proﬁling
at single-base resolution for ﬁne-mapping epigenetic disease loci by
contrasting associations with similar adipose tissue proﬁling effort by
the 450K array [35]. Of the replicated disease loci where at least two
CpGs were covered by MCC-Seq, including one overlapping a significant metabolic disease CpG from the array-based study, w90% of the
top associating CpGs were found to locate proximally but not directly
overlapping the array-based disease CpGs [35].
Investigations by Cheung et al. using MCC-Seq in a range of tissues,
including visceral adipose tissues, further demonstrated that a large
fraction of CpG methylation under genetic regulation is tissue-speciﬁc
(>50%) and maps preferentially to enhancer elements [71]. This estimate of the genetic impact on methylation was conﬁrmed for
disease-linked CpGs (>55%) identiﬁed from visceral adipose tissue
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proﬁles [34,35]. Importantly, complex trait-associated CpGs discovered in the disease-relevant adipose tissue that additionally replicated
across tissues to the bioavailable whole-blood tissue, using matched
samples, were found to exhibit even stronger genetic regulation
(>90%) [35]. This observation indicates that the full depth of epigenetic impact on disease cannot be properly captured when employing
cross-tissue validations from bioavailable to disease-linked tissues, as
is currently being applied in many reported EWAS. Validation across
well-phenotyped biologically relevant tissues of the same tissue type is
needed to further explore and conﬁrm current observed trends of
complex trait-linked epigenetic variants. Allum et al. further provided
functional insight for a fraction of lipid-linked GWAS SNPs, which were
found to be enriched in SNP-CpG pairs overlaying adipose tissue
regulatory regions that mapped with blood lipid-associated CpGs [35].
For instance, the authors highlighted HDL cholesterol-linked SNPs [73]
mapping to an intragenic region of the metabolic disease GALNT2
locus that exhibited putative regulatory effects on a nearby adipose
tissue-speciﬁc enhancer element. This enhancer region was found to
harbor HDL cholesterol-associated CpGs not detectable through the
450K array method [35]. These ﬁndings exemplify the advantage of
using integrational approaches of association studies at single-base
resolution to permit functional annotation of GWAS SNPs identiﬁed
from large-scale efforts.
8. CAVEATS IN METHYLOME-BASED DISEASE ASSOCIATION
STUDIES
Although epigenetic signals are known to be cell-speciﬁc, most published epigenome-wide studies to date have investigated correlations
to complex traits in heterogeneous tissues. Although laboratory and
statistical methods for cellular decomposition of whole blood samples
are currently being applied, these are not easily transferrable to primary tissues such as adipose tissue, where many unknowns remain in
terms of cellular makeup. To account for tissue heterogeneity in adipose EWAS, investigators have predominantly integrated BMI measures as a surrogate to indicate levels of adipose tissue heterogeneity
[34,35,74]. Although BMI does not necessarily mirror body fat distribution, Laforest et al. have shown that across multiple techniques
tested for adipose cell size, a general pattern of association between
this measure and BMI is noted e indicating that BMI can be used as a
proxy for cellular heterogeneity [74].
Nevertheless, more precise estimates that better reﬂect an individual’s
adipose tissue composition are warranted to account for the impact of
tissue heterogeneity in EWAS. For instance, we know that visceral adipose tissues of obese individuals undergo important remodeling and
inﬁltration by immune cell types such as macrophages, but estimates
are hard to evaluate in large-scale studies. Efforts from large consortia
are providing more and more reference epigenome maps to be used for
tissue dissection purposes. Targeted puriﬁed primary cell-based studies,
such as the one from Bradford et al. that contrasts epigenome proﬁles of
adipocytes from different fat depots [32], further provide insight to the
community to help pinpoint observed signals and decipher how epigenetic changes translate mechanistically. Similarly, studies using singlecell technologies are crucial to elucidate cellular components of diseaselinked primary tissues. A recent report by Vijay et al. used single-cell
RNA-Seq to proﬁle the stromal fraction of 12 visceral and 13 subcutaneous adipose tissue samples, enabling the discovery of crucial differences in cellular composition between these fat depots [75].
Together, these efforts will allow for the implementation of referencebased or supervised deconvolution methods in complex tissue-based
EWAS similar to what is already available for studies of whole blood

[76]. Similarly, efforts to improve reference-free/unsupervised deconvolution methods will also be beneﬁcial to help correct currently used
statistical models in disease dissection. Brieﬂy, these methods use an
approach that does not require any additional input of reference
methylomes to determine cofactors from methylation levels that correspond to cellular components of tissues among others. These cofactors
can then be added to the statistical model to correct for tissue heterogeneity and other components. As previously stated here, most methods
developed for this purpose have been benchmarked in whole blood
samples, whereas their application in complex primary tissues remains
to be validated. For instance, the publicly available Reference-Free
Adjustment for Cell-Type composition (ReFACTor) software was
released in 2016 and uses principal component analyses on a subset of
differentially methylated regions to provide approximates of variables to
be used in EWAS models [77]. While the expectation is that top variables
pulled out by the software will correspond to cellular components of the
tissue, testing the technique within cancerous breast tissues showed
that variables corresponding to other components such as disease
status were instead highlighted [78]. Another technique developed in
2016 by Houseman et al. called RefFreeCellMix is based on naive matrix
factorization (NMF) and was benchmarked on methylation levels from
multiple tissue cohorts proﬁled on Illumina arrays [79]. More recently,
MeDeCom, which uses NMF as with RefFreeCellMix, was released;
however, it also applies constraints based on DNA methylation behavior
in pure cell populations to improve latent methylation component prioritization [80]. In their proof-of-concept paper, the authors showed that
MeDeCom outperformed RefFreeCellMix when identifying cellular
components in more complex samples [80]. Extrapolation of these algorithms for use on single-base resolution methylomes as opposed to
array-based data will be useful in future epigenomic studies.
As previously stated here, epigenetic traits are known to be modulated
by both environmental and genetics effects and, thus, can be seen as
reﬂecting the interplay between these drivers of complex disease.
However, an important question remains in terms of dissecting the
exact contribution of these two modules to epigenetic mark variation.
For example, in instances of integrative data gathering (i.e., genotypes,
epigenetic traits, and phenotypes), the user can dissect genetic and
potential environmental contributions to the identiﬁed epigenetic signatures by conditioning association models on the top-linked SNPs
[35]. This method is particularly useful when investigating epigenetic
trait data in population-wide studies, and more powerful when gathering information at single-base resolution. However, to fully account
for genetic confounding factors in studies seeking to identify epigenetic
modulations associated with disease, a discordant twin model of
monozygotic twins is ideal [33,81e83].
Finally, a consequence of generating epigenome maps in crosssectional cohorts is that it does not permit for causality inference of
the epigenetic change on complex traits (Figure 1). While longitudinal
study models and functional validation would be ideal to investigate
this type of relationship, statistical models have been developed to
infer the direction of the causal link between associated epigenetic and
complex traits. The most commonly applied of these models is Mendelian randomization (MR). Brieﬂy, MR uses an instrumental variable
(IV) in the form of SNPs linked only to the exposure under study, given
that they are not prone to reverse causation, to determine the direction
of effect between the exposure and the outcome. Relating to epigenetic
traits such as DNA methylation, causal effects may only be explored at
CpGs exhibiting genetic linkage. Applying the statistical method of MR,
Dekkers et al. substantiated ﬁndings that support an effect of circulating lipid status on correlated methylation levels [84]. Similar ﬁndings
were reported by Mendelson et al. for the inﬂuence of BMI on
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methylation levels at a proportion of identiﬁed BMI-linked CpGs [67].
Whereas in their large-scale methylome study of 139 complex traits,
Richardson and colleagues were unable to resolve causality with MR
due to horizontal pleiotropy, MR ﬁndings were used to prioritize potential mediation effects by GWAS SNPs on gene expression through
DNA methylation for over 300 CpG-SNP pairs [85]. However, all these
ﬁndings were gathered from whole-blood DNA methylation and were
not corroborated in disease-relevant tissues, making translation into
biological knowledge challenging. While Wahl et al. have made strides
in this aspect by presenting similar results for the impact of BMI on
CpG methylation in subcutaneous adipose tissue [68], further investigation in more tightly disease-linked tissues is needed to conﬁrm this
trend. Furthermore, given that these studies used the 450K array, the
direction of causality of methylation in metabolic disease studies at
regulatory regions lying outside of promoters (i.e., distal enhancer
elements) has not yet been evaluated. These assessments will be
crucial in future complex disease etiology studies.

the 4D Nucleome project are ongoing to generate reliable genomic
interaction proﬁles in obesity-related cell types such as differentiated
adipocytes. Finally, proﬁling novel histone modiﬁcations, such as
propionylation and butyrylation, in metabolic disease-linked tissue
models will allow additional insight into epigenome perturbation and
disease susceptibility [91].

9. CONCLUSIONS AND FUTURE DIRECTIONS

The authors declared no conﬂict of interest.

Fast-paced progress has been made in the ﬁeld of functional epigenomics, both in terms of technological advancement to study epigenomes, as well as our ability to apply these technologies in large
cohort studies. Functional epigenome proﬁles exhibit tissue and cellspeciﬁcity, yet most epigenome-wide studies of metabolic traits
have been conducted in whole-blood tissues due to easy access, as
opposed to tissues that are more targeted to the disease model such
as visceral adipose or liver tissues. Whole-genome methylation
proﬁling across a large number of human tissues has conﬁrmed that
enhancer regionseknown to play a role in gene expression modulationdare predominantly tissue- and cell-speciﬁc [58]. Comprehensive studies correlating methylation status to metabolic traits using
array-based technologies biased toward promoter regions have provided signiﬁcant but restricted insight into disease etiology, due to the
static nature of these elements. The advent of targeted single-base
resolution technologies, such as MCC-Seq, coupled with the availability of well-phenotyped clinically relevant cohorts have provided
increased discovery power for the detection of biologically relevant
trait-linked epigenetic variants.
An important point of future exploration to assess the full contribution of
epigenetic variants in metabolic disease outcome will be to progress
toward assessing the ability of epigenetic marks to predict future disease risk. In fact, a recent longitudinal EWAS study in more than 10,000
individuals reported by Agha et al. showed the predictive nature of
methylation status on myocardial infarction onset at more than 50 CpGs
detectable on the 450K arrayeindicating that methylation status can be
used as an indicator of future complex disease development [86].
Moreover, population-based epigenome-wide studies have been
mostly centered on linking variation to disease models. However, the
issue remains that many metabolic disease-related traits, such as fat
distribution, depict sexual dimorphism [87e89], which remain uncharted in terms of epigenome maps. Large-scale well-phenotyped
cohorts within disease-targeted tissues extracted from both males and
females are needed to study these effects in more detail and permit us
to better treat metabolic disease in the dimorphic human population.
This will be an interesting area of future exploration.
Additional high-resolution integrational approaches to link identiﬁed
disease-associated epigenome changes to target genes are needed.
Here, the advent of chromatin conformation and editing technologies in
disease-linked cell types are promising [90]. For instance, efforts from
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